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ABSTRACT
Objective: To identify ways that provision of hemophilia care can be maximized at the local
level, irrespective of available resources or cultural or geographic challenges.
Methods: The SHIELD1 group used its multinational experience to share examples of local
initiatives that have been employed to deliver optimal hemophilia care.
Results: The examples were reviewed and categorized into four key themes: guidelines and
algorithms for delivery of care; collaboration with patients and allied groups for care and
education; registries for the monitoring of treatment and outcomes and health care planning
and delivery; and opportunities for personalization of care. These themes were then
incorporated into a road map for collaborative care in hemophilia that reflected the
contribution of best practice.
Discussion: Differing healthcare reimbursement systems, budgetary constraints, and
geographical and cultural factors make it difficult for any country to fully deliver ideal care
for people with hemophilia. The SHIELD approach for collaborative care provides illustrative
examples of how four key themes can be used to optimize hemophilia care in any setting.
Abbreviations: AHCDC: Association of Hemophilia Clinic Directors of Canada; AICE: Italian
Association of Hemophilia Centres; ATHN: American Thrombosis and Hemostasis Network;
EAHAD: European Association for Haemophilia and Allied Disorders; EHC: European Hemophilia
Consortium; FIX: Coagulation Factor IX; FVIII: Coagulation Factor VIII; HAL: Haemophilia Activity
List; HJHS: Haemophilia Joint Health Score; HTC: Hemophilia Treatment Centre; HTCCNC:
Hemophilia Treatment Centre Collaborative Network of China; MASAC: Medical and Scientific
Advisory Council; MDT: Multidisciplinary team; NHD: National Haemophilia Database; NHF:
National Hemophilia Foundation; PK: Pharmacokinetics; POCUS: Point of care ultrasound; PWH:
People with haemophilia; SHIELD: Supporting Hemophilia through International Education,







Hemophilia is a rare X-linked bleeding disorder affecting
approximately 400,000 people globally, caused by a
deficiency of coagulation factor VIII (FVIII) (in hemophilia
A) or factor IX (FIX) (in hemophilia B) [1,2]. Current man-
agement of hemophilia involves treatment with either
plasma-derived or recombinant factor VIII or IX products,
ideally on a prophylactic basis for moderate and severe
patients [2–4]. The World Federation of Hemophilia
(WFH) guidelines, first introduced in 2005 and updated
in 2012, offer practical recommendations for the
diagnosis and management of hemophilia and guidance
on the management of complications, such as musculos-
keletal issues, inhibitors and transfusion-related infec-
tions [2]. However, there are multiple challenges to the
funding and implementation of high quality, guideline
driven, evidence based hemophilia care [4]. The rarity
of hemophilia may limit recognition and availability of
tools and resources to confirm a diagnosis as well as
restrict options for management of the disease and its
complications. Funding may be inequitable, inconsistent,
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incomplete or absent, and further complicated by politi-
cal and bureaucratic processes in place for its adminis-
tration. Adherence to treatment recommendations and
follow up is an ongoing challenge common to long-
term medical conditions [5]. Data suggest that up to
20% of people with hemophilia (PWH) do not follow
their prescribed treatment [6,7].
Differing healthcare reimbursement systems, bud-
getary constraints, and geographical and cultural
factors, make it difficult for any country to fully
deliver ideal care. Some regions, mainly developed
countries, may have sufficient treatment product avail-
able but then have a higher expectation of outcomes
and often insufficient supportive care experience and
personnel to monitor adherence and outcomes and
implement regular follow-up [8]. In contrast, develop-
ing regions may not have ready access to factor repla-
cement but have developed excellent physiotherapy
and rehabilitation programs. As a result, it is impossible
to compare and contrast care quality and create
models of care according to resources alone. Is it
time therefore to move away from the pursuit of one
perfect model and, instead, learn from global simi-
larities and differences in the delivery of hemophilia
care and focus on building the best approach tailored
to each healthcare system and patient population?
Working together to deliver ideal care
The SHIELD group: Supporting Hemophilia through
International Education, Learning and Development
is an international panel of independent experts dedi-
cated to the sharing of best practice and education in
the management of hemophilia. A key element of
SHIELD’s work is to share its multinational experience
of hemophilia care across a variety of different settings
and discuss the respective constraints to delivery of
ideal care. This manuscript summarizes that discussion
within a framework of four key themes – the availability
and use of guidelines and algorithms for hemophilia
care; how organizations can work together in the deliv-
ery of care; the role of patient registries; and personali-
zation of care. The goal is to provide both specialist and
non-specialist health care professionals who treat these
patients with examples of evidence based best practice
to enhance their approach to care.
Themed discussions are accompanied by summary
recommendations, developed by the SHIELD group
during the development of this manuscript and other
educational materials, based on individual clinical
experience and published evidence. These are incor-
porated into a collaborative road map (Figure 1) with
the specific aim of guiding delivery of care regardless
of setting and resources. Consistent feedback demon-
strates how ongoing experience and new evidence,
at both a global and local level, facilitates continuous
improvements in care delivery.
Key themes in the delivery of ideal
hemophilia care
I - Guidelines and algorithms for hemophilia
care
Guidelines aim to summarize published literature and
expert consensus in order to harmonize the principles
of care delivery around the world. The US Institute of
Medicine states that clinical practice guidelines should
be ‘ … informed by a systematic review of evidence
and an assessment of the benefits and harms of alterna-
tive care options’ [9]. Whilst this may be possible when
developing clinical guidelines for diseases affecting
large patient populations, the reality for rare diseases
like hemophilia is that large, randomized studies to
inform evidence-based recommendations are limited.
As a result, alternative trial designs are needed to
optimize the use of available patient data [10].
A standardized approach to the management of
rare diseases is important to enable faster initiation of
treatment, improve cost-effectiveness of treatment
and facilitate the tracking of treatment utilization.
Whilst guidelines are usually based on global rec-
ommendations for models of care, algorithms can be
country-specific. In some cases, they may even be
centre-specific and reflect local needs of the patient
population and localization of skills and resources to
meet those needs.
Global guidelines have a key role to play in high-
lighting new knowledge that can advance the compre-
hensive management of hemophilia care. The
availability of high-quality data establishing the
efficacy and superiority of prophylactic factor replace-
ment over episodic treatment of hemophilia and the
need for greater use of validated, disease-specific
assessment of care outcomes was a driving factor for
the WFH to update its guidelines in 2012 [2]. These
guidelines are typically adapted for use at the national
or even local (institutional) level, a process that can lead
to a duplication of effort across regions. Their broad
content allows for selection of relevant recommen-
dations and adaptation to meet the specific needs of
PWH at this local level. However, the extent to which
global guidelines are reflected in local models of hemo-
philia care varies not only according to available
resources but also to geography, regional alignment
and sociocultural and political factors, often resulting
in a ‘blending’ of global WFH and local guidelines.
The Nordic Haemophilia Council (www.
nordhemophilia.org), a body of hemophilia experts
from the five Nordic countries (Denmark, Sweden,
Norway, Finland and Iceland) regularly publishes and
renews regional guidelines for hemophilia [11]. The
Italian Association of Hemophilia Centres’ (AICE) treat-
ment guidelines for Hemophilia Treatment Centres
(HTCs), based on published literature and scientific evi-
dence, are usually updated every three years.
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Global guidelines can even be adapted for those
PWH living some distance away from treatment
centers. In Colombia, treatment centers design home
self-infusion protocols (based on the WFH guidelines)
for patients who are receiving prophylaxis and living
in remote areas. In 2015, the country’s National Ministry
of Health issued its own guideline for prophylaxis in
patients with severe hemophilia without inhibitors,
resulting in 82% of severe patients now receiving pro-
phylaxis [12].
In recent years, there has been a large body of data
supporting the value of a collaborative multidisciplin-
ary team (MDT) in delivering effective and optimal
care for patients with bleeding disorders [13]. It
builds on the WFH recommendations around provision
of comprehensive care to address the wide-ranging
needs of PWH and their families via a MDT of health-
care professionals with expertise and experience to
attend to the relevant physical and psychosocial
health issues, including but not limited to physicians,
nurses, physiotherapists, and social workers [2]. This
model of care is relevant, irrespective of the availability
of factor concentrate. In the United States, to be con-
sidered as federally qualified and be eligible for
federal funding, an HTC is required to have a core
team of specialists in place [14]. A commitment ‘… to
treat the whole person and the family, through continu-
ous supervision of all the medical and psychosocial
aspects of bleeding disorders’ is mandated within the
establishment of a comprehensive HTC [15].
Recommendations from the Medical and Scientific
Advisory Council (MASAC) of the National Hemophillia
Foundation (NHF) list the social worker as a primary
member of this MDT with a remit to ‘… assist in the
issues of daily living, such as adjusting to hemophilia
and locating resources (e.g. insurance, transportation
and housing)’ [16]. Other organizations, such as the
European Association for Haemophilia and Allied Dis-
orders (EAHAD), support guidelines aimed at specific
disciplines, for example, those published recently for
nurses working in hemophilia care [17] and a planned
curriculum for physiotherapists. The organization also
contributes to the development of basic principles of
hemophilia care [18]. Many HTCs regularly interact
with local emergency departments to develop and
update treatment algorithms that help in the initiation
of immediate, appropriate therapy while waiting for
advice from the HTC.
SHIELD recommendations:
. Global guidelines provide a useful overview of the
ideal standard of care. Identify the key priorities for
the PWH in your region and select the elements of
the available guidelines that are relevant and
achievable.
. Review other national or regional guidelines for
models of local adaptation.
. Identify other HTCs with similar hemophilia popu-
lations and tailor their examples of algorithms of
care, derived from global guideline elements, to
the needs of local PWH.
Figure 1. A road map for collaborative care in hemophilia summarizing the SHIELD recommendations, potential outcomes and
examples of how resources and best practice can contribute within a themed framework.
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. Work within HTCs to maximize resources and avail-
able personnel to optimize delivery of care in
accordance with these adopted guidelines and
algorithms.
II - Organizations working together in the
delivery of care
When PWH, their families and healthcare providers col-
laborate, it has a positive impact on care and outcomes.
There are two emblematic examples of the importance
of such alliances in hemophilia care. The first, the WFH,
was conceived as a joint venture between PWH and
physicians; it was founded by a patient and its presi-
dent is a patient. The second, the European Hemophilia
Consortium (EHC; www.ehc.eu), is a non-profit organiz-
ation that represents 45 national patient organizations
from 27 member states of the European Union. It is
involved in supporting both patient associations and
medical research. Comprehensive care, as delivered
by HTC networks, is an important illustration of how
organizations can work together to address and
deliver the needs of local PWH. Studies have shown
the importance of a dedicated HTC in helping patients
with inhibitors and increasing patient adherence to
treatment [19].
The size and complexity of care delivered by these
HTCs can vary from region to region. In Italy, 57 HTCs
within the AICE national network aim to harmonize
patient management across 21 regions. A small
number are classed as comprehensive care centers
and offer specialized care including orthopaedic
surgery and management of complex cases, such as
inhibitor patients. In Colombia, management of inpati-
ent care, surgery and emergency care is divided across
25 large centers situated in the main cities, all staffed
by physicians specialized in hemophilia care. These
centers also coordinate the home-delivery of factor
for prophylaxis and on-demand treatment for patients
living in remote or hard to access areas.
Working with patient organizations can help build
awareness of hemophilia, influence healthcare policy,
coordinate care standards and deliver standardized
education to healthcare providers as well as PWH and
their carers [17,20]. The mechanisms by which these
organizations work together varies widely. In Canada,
medical directors of the 25 HTCs make up the Associ-
ation of Hemophilia Clinic Directors of Canada
(AHCDC). The organization works to establish national
standards of care in conjunction with the different
associations comprising nurses, physiotherapists or
social workers, as well as patients via the Canadian
Hemophilia Society. This cooperation has been crucial
to the introduction of a new national registry and
ongoing negotiation with government for support of
the HTC network and funding for current and novel
treatment products.
There are other country-specific examples of collab-
oration. In China, rapid growth in the number of HTCs –
from six to 50 between 2004 and 2016 – and the work
of the organization, Hemophilia Home of China, has
increased public awareness of hemophilia and led to
greater coverage of the cost of concentrates by
health insurance companies. In Germany, training
camps set up by patient organizations supplement
the work of HTCs in instructing patients around self-
infusion and guiding treatment. In Sweden, healthcare
providers work with the Swedish Hemophilia Society to
develop patient information that is distributed via
leaflets or booklets, online, at conferences and via
summer camps. In Turkey, the first local Hemophilia
Association was established in İzmir 20 years ago.
Within 10 years, a Hemophilia Federation, comprising
12 regional associations throughout Turkey, was
achieved. Since then, the organization has conducted
educational meetings for clinicians, nurses and patients
and parents, some in distant cities bordering with Syria,
Iraq and Iran. In France, a similar collaboration led to an
online training program dedicated to patients with
mild hemophilia (www.hemomooc.fr), as well as an
outreach program for females from families with
hemophilia regarding their genetic and bleeding
risks, diagnostic approaches and reproductive
options. The United Kingdom Haemophilia Centre
Doctors Organisation, established in 1968, oversees
guideline publications covering topics such as joint
bleeds and immune tolerance induction [21,22] and
maintains a comprehensive national registry and
online patient treatment record (Haemtrack; www.
haemtrack.mdsas.com).
SHIELD recommendations
. Partner with national and local patient organizations
to deliver education programs to healthcare provi-
ders, PWH and their families using innovative
formats such as summer camps as well as standar-
dized web-based education programs.
. Partner with patient organizations to increase hemo-
philia awareness and advocacy.
. If there is no patient organization, encourage the
setting up of one that can work at local level with
a HTC or at national level with a network of HTCs.
III - Disease registries
The expression ‘You have to know where you are to
know where you are going’ is directly relevant to the
role of disease registries. These databases, comprising
either individual or aggregate patient data, can
further the understanding around variations in treat-
ment; describe care patterns, including appropriate-
ness and disparities in the delivery and quality of
care; examine factors that influence prognosis and
quality of life; and provide evidence on resource utiliz-
ation [23]. In addition, data regarding treatment
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outcomes may serve to inform guideline content in the
absence of large-scale randomized controlled trials.
When looking at hemophilia specifically, national
registries provide valuable insights into the variability
of the PWH population in terms of prevalence, demo-
graphics and management from country to country.
When linked to global guidelines for hemophilia, they
can help to improve the diagnostic approach, treat-
ment planning and delivery of care, and government
resource allocation based on WFH priorities and popu-
lation characteristics for that country. For example,
details of therapy and bleeds for all patients with
hemophilia are continuously updated in the Swedish
Hemophilia Registry (www.kvalitetsregister.se). In
Italy, all HTCs contribute to the National Registry,
sending local epidemiological data and details of
disease severity and treatment regiments to the AICE
database via an electronic platform. The National Insti-
tute of Health (ISS) is responsible for the analysis and
dissemination of this data, and AICE uses the database
as a research tool for clinical studies [24]. In China,
patient members of the National Registered Center
have now reached more than 13,000 and the data
are used to improve rates of diagnosis and hemophilia
knowledge, as well as explore China’s national treat-
ment environment. In the UK, an individual’s longitudi-
nal ‘steady state’ treatment on-line record (Haemtrack),
musculoskeletal health measures (Haemophilia Joint
Health Score; HJHS) and, increasingly, the Haemophilia
Activity List (HAL) all inform this process. They also
enrich clinic visits and also contribute to national epi-
demiology via the National Haemophilia Database
(NHD). In France, the publicly-funded FranceCoag reg-
istry is a comprehensive, national project incorporating
clinicians, patients and government authorities. It facili-
tates links within the community, harmonizes hemo-
philia care and permits specific research studies
based on real world data [25].
Registries can provide information on the use of
treatment products, including the monitoring of pro-
phylaxis and immune tolerance induction (ITI), data
which are not always gathered by healthcare providers
within the formal setting of the HTC. In Germany, home
treatment is monitored by the HTC and patient entry of
each infusion (time, reason, amount, batch number) in
a diary, either in paper or electronic form, is mandatory
according to the German transfusion law. Canada has
recently introduced a national registry system that
monitors home infusions. Information is entered elec-
tronically by patients and then analyzed to determine
the appropriateness of the treatment regimen and
track product inventories and utilization. Most HTCs
in the United States participate in a registry through
the American Thrombosis and Hemostasis Network
(ATHN), a non-profit organization dedicated to collect-
ing and collating national patient data. In addition to
information entered by the HTCs, patients can also
self-enter bleeding and treatment data into the registry
using Advoy, a web-based electronic bleeding and
infusion log (https://athnadvoy.athn.org), which can
then be used to evaluate effectiveness of treatments
and outcomes. The demands placed on these diverse
registries will continue to evolve in parallel with the
ambition to share meaningful outcomes data and
ensure close pharmacovigilance as new products
come to market and inform the different national pro-
curement processes.
Collaboration by all organizations involved in hemo-
philia care can contribute to data collection around
complications, such as emergency room visits, hospital-
ization, inhibitors, comorbidities and burden of disease.
Such data can help health care systems follow trends
and improve knowledge of both the national and
local care situation and track respective outcome
measures. For example, in 2015, the National Health-
care System in Colombia created a mandatory annual
registry, the High Cost Account [12], generating a com-
plete clinical and administrative report which allows for
patient follow-up and identifies strengths and weak-
nesses in the assistance process. The registry includes
2059 patients with hemophilia of which almost half
are under 20 years of age. The High Cost Account
shows the risk management indicators and motivating
factors involved in patient care that improve interven-
tions performed at all levels and progressively achieves
substantial improvements in healthcare and quality of
life.
SHIELD recommendations
. If there is no national registry available, look at the
data gathered by other regions and explore oppor-
tunities to share methodologies.
. If there is a registry, use the real-time patient data
provided to raise awareness of hemophilia and the
burden of disease, particularly in terms of quality
of life, and establish key epidemiological
benchmarks.
. Use treatment and outcomes data to develop cost
utility arguments to drive improvements in resour-
cing hemophilia care.
IV - Tailored personalized care
The concept of personalized medicine results from the
recognition that specialized diagnostic tests can help in
the prescription of treatment that involves ‘the right
person, the right drug at the right dose, and right
time’ [26]. In hemophilia, tailored personalized care
involves the adaptation of treatment to life stage,
bleeding frequency and lifestyle [2,27]. More specifi-
cally, the dose and frequency of infusions depend on
pharmacokinetic (PK) properties of the specific
product in addition to patient factors such as age,
joint status, activity profile, lifestyle, access to home-
care, vascular access, and parental and patient
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capabilities and understanding of the disease [28].
The future availability of new therapeutic approaches
for hemophilia may enhance the need for
personalization.
Accurate diagnosis of hemophilia guides appropri-
ate personalized care [2], but diagnostic certainty
about a bleed and subsequent recovery can be challen-
ging; both PWH and clinicians can find it difficult to be
certain if pain is attributable to an acute bleed [29].
Studies suggest that the correct, clinical diagnosis is
made in fewer than 50% of cases in the absence of
imaging [30,31]. Utilization of point of care ultrasound
(POCUS) is increasingly helpful in confirming a bleed
and determining whether it is intra-or extra-articular
[32]. However, in many of the countries where PWH
receive home treatment, the current principle of care
is that the patient determines whether the symptoms
warrant early intervention to manage a bleed.
Prophylaxis with regular infusion of either plasma-
derived or recombinant factor VIII or IX products is
the cornerstone of modern hemophilia care based on
evidence of effectiveness in the prevention of bleeding
and joint destruction in patients with moderate and
severe disease [2,33]. The timing of initiation of prophy-
laxis i.e. whether at the first bleeding episode or before
the age of two, and how long it continues, is subject to
the constraints of local guidelines, population needs
and budget availability [34]. Dose and frequency
should be adjusted according to individual PK, bleed
frequency and changing needs during growth [28].
However, the optimal regimen continues to be
explored. The Canadian Hemophilia Prophylaxis Study
examined escalating prophylaxis from one to three-
times weekly, depending on a patient’s bleeding
pattern [35,36]. In Sweden, all patients with severe
and moderate hemophilia (and in special circum-
stances even mild) are offered prophylactic therapy
with mainly recombinant FVIII and FIX products in
accordance with the WFH guidelines. In Italy, prophy-
laxis is mainly implemented in severe and moderate
patients at an average of three infusions per week in
severe hemophilia A and twice weekly in severe hemo-
philia B. Although the majority are treated with recom-
binant products, there is still a group of patients treated
with plasma-derived products. Prophylaxis for children
in the United States with severe hemophilia typically
starts around 1 to 2 years of age (or after the first
major bleed), with a goal of alternate daily infusions
for hemophilia A and once to twice weekly for hemo-
philia B. Standard half-life recombinant factor products
are predominantly used but extended half-life pro-
ducts are gaining popularity and a small subset of
patients, usually those with high concern for inhibitor
development, are electing to use plasma-derived pro-
ducts. Treatment individualization by means of PK
assessment and careful evaluation of bleeding pheno-
type, including ultrasound detection of early
arthropathy, has been increasingly adopted over the
last few years.
The tailoring of prophylactic regimens to lifestyle
means that participation in physical activity and
regular attendance at school or work can be encour-
aged. The benefits of regular exercise, in terms of
fitness and improvements in joint, bone and muscle
health, are well-recognized [2,37]. Working with other
members of the MDT, physiotherapists play a key role
in helping PWH to identify a suitable type and level
of physical activity in which to participate [38]. The
value of close MDT involvement and support is demon-
strated by the higher than expected adherence to pro-
phylaxis in adolescents and young adult PWH in a
recent UK study by van-Os et al. [39].
Ultimately, PK measurements may help to define the
best dosing schedule for each patient [28] and a popu-
lation PK evaluation makes this more practical in the
clinical setting [40]. An approach where FVIII trough
levels are maintained above 1% has been shown to
reduce the risk of a bleed when compared with the
time spent with FVIII plasma levels below 1% [41].
However, prophylaxis must consider individual PK
differences that affect the duration of action of replace-
ment factor (FVIII recovery, half-life and clearance) in
the hemophilia population [27,28]. In China, the
search for an individualized, cost effective and afford-
able prophylaxis regimen to reduce joint bleeding to
an acceptable level remains a work in progress [42-
44]. Preliminary efficacy results with PK-tailored tertiary
prophylaxis, started after a bleed has occurred in chil-
dren with severe hemophilia A, show that it may be
the most cost-effective individual prophylaxis
approach [45]. In response to the lack of affordability
of standard full-dose prophylaxis for most families in
China, the Hemophilia Treatment Centre Collaborative
Network of China (HTCCNC) has begun studies evaluat-
ing the delivery of low-dose prophylaxis in boys with
severe hemophilia A (10 IU/kg twice a week) and
hemophilia B (20IU/kg weekly) [46].
Once an appropriate prophylactic regimen has been
established, management of PWH should take place in
a home therapy setting where appropriate and the age
and activity of the patient and other family lifestyle
issues have been considered. Home therapy facilitates
immediate access to clotting factor and optimal treat-
ment, and has been shown to decrease pain, dysfunc-
tion and long-term disability as well as significantly
decrease hospital admissions due to complications
[2]. Treatment effectiveness is also improved when
the time between bleeding onset and infusion is mini-
mized, especially for patients with inhibitors [47]. Edu-
cation around the management of infusions and close
supervision is essential for successful home therapy,
and patients need to be able to manage an emergency
promptly. For some PWH, lack of skills and confidence
in self-management may prove to be a barrier.
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Similarly, parents may also lack confidence in caring for
a child with a bleeding disorder. Global initiatives such
as the Parents Empowering Parents program (www.
pepprogram.org) provide training to bolster parents’
confidence and professional knowledge-base regard-
ing issues related to parenting and family management
for parents of children with a bleeding disorder.
Beyond its role in acute care, the MDT is crucial fol-
lowing an acute joint or muscle bleed or after any sur-
gical procedure. Rehabilitation is important for
functional improvement and recovery after musculos-
keletal bleeds and for those PWH with established hae-
mophilic arthropathy [2]. In the UK, the HJHS and HAL
responses provide the MDT, and the physiotherapist in
particular, with a baseline for the rehabilitation process.
Recently, some centers have added routine POCUS
assessment of key joints (elbows, knees and ankles)
to identify demonstrable architectural change that is
not yet symptomatic and to assist in treatment and
rehabilitation. The physiotherapy team then agrees
on a realistic muscle strengthening and joint stabilizing
regimen, which may require several weeks or months
for a serious bleed (e.g. psoas).
SHIELD recommendations
. Educate PWH and their carers to improve recog-
nition of a bleed and achieve prompt initiation of
treatment.
. Identify barriers to optimal personalized care, for
example, lack of confidence to manage home
therapy or concerns around participating in physical
activity, and look at programs that help to address
these.
. Use patient data around infusions, bleeds and life-
style to identify effective strategies that could be
used on a wider basis.
Areas for further thinking and research
Careful examination of these overarching themes in
the successful comprehensive care of PWH illuminates
many of the barriers to achieving that ideal model of
care. Many have been discussed already and some,
like funding inequities and administrative processes,
result from political and systemic factors that are
beyond the remedy of the hemophilia care provider.
However, other challenges may be amenable to
change at the level of the HTC or local organization
and should be considered in future research and
resource planning. Many barriers to home therapy
might be addressed by the local community, which
could, in turn, impact on strategies for improved adher-
ence to therapy, particularly among adolescent PWH.
We have presented some different strategies for prophy-
laxis, but ultimately these regimens must be maximized
within the unique local context to ensure both cost and
clinical effectiveness. Finally, as registries develop and
hemophilia treaters rely increasingly on the evidence
available to inform clinical decisions, the definition of
the minimal data set and key outcome measures is criti-
cal to facilitate both regional and international evalu-
ation of care and outcomes to drive best practice.
Conclusion
Provision of primary prophylaxis for all moderate and
severe PWH under the careful and regular monitoring
of a comprehensive multidisciplinary team, is an admir-
able and reasonable goal. The members of SHIELD
recognize that this ideal may not be fully achievable
in any setting. However, multiple elements of best
practice can contribute to the delivery of the best poss-
ible care, as listed in the recommendations and illus-
trated in Figure 1. Patient communities are highly
variable between countries and patient needs and
expectations are also evolving at a rapid pace. Care and
support infrastructure may be at very different stages
in different regions. Finally, new therapeutic options,
including non-replacement therapies and gene
therapy, are rapidly changing the treatment paradigm.
Capturing the diversity of experience from around
the world and sharing examples of best practice in col-
laboration between clinics, regions, and countries, as
illustrated in Figure 1, is a founding principle of the
SHIELD group. Ultimately, we hope that this will contrib-
ute to the creation of an adaptable model of care which
is grounded in global evidence but able to adapt orga-
nically to these different influences and lead to better
treatment outcomes for all persons with hemophilia.
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